153 related articles for article (PubMed ID: 21182128)
1. Optimization of single injection liver arterial phase gadolinium enhanced MRI using bolus track real-time imaging.
Sharma P; Kalb B; Kitajima HD; Salman KN; Burrow B; Ray GL; Martin DR
J Magn Reson Imaging; 2011 Jan; 33(1):110-8. PubMed ID: 21182128
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient.
Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC
J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging.
Schneider G; Altmeyer K; Kirchin MA; Seidel R; Grazioli L; Morana G; Saini S
Invest Radiol; 2007 Feb; 42(2):105-15. PubMed ID: 17220728
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A
J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
[TBL] [Abstract][Full Text] [Related]
5. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
[TBL] [Abstract][Full Text] [Related]
6. Clinical implication of small (<20 mm) enhancing hepatic nodules observed only during three-dimensional gadobenate dimeglumine-enhanced hepatic arterial-phase MRI of the hepatitis B virus-induced mild cirrhosis.
Kim YK; Lee YH; Kwak HS; Kim CS; Han YM
Clin Imaging; 2008; 32(6):453-9. PubMed ID: 19006774
[TBL] [Abstract][Full Text] [Related]
7. MRI findings of hepatocellular carcinoma.
Wiwanitkit V
Magn Reson Imaging; 2011 Feb; 29(2):303. PubMed ID: 21129874
[No Abstract] [Full Text] [Related]
8. Three-dimensional contrast-enhanced hepatic MR imaging: comparison between a centric technique and a linear approach with partial Fourier along both slice and phase directions.
Kim KA; Herigault G; Kim MJ; Chung YE; Hong HS; Choi SY
J Magn Reson Imaging; 2011 Jan; 33(1):160-6. PubMed ID: 21182134
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of abdominal organs on hepatic arterial phase: quantitative comparison between 1.5- and 3.0-T magnetic resonance imaging.
Goncalves Neto JA; Altun E; Elazzazi M; Vaidean GD; Chaney M; Semelka RC
Magn Reson Imaging; 2010 Jan; 28(1):47-55. PubMed ID: 19577399
[TBL] [Abstract][Full Text] [Related]
10. Time-resolved contrast-enhanced magnetic resonance angiography (CEMRA) of the left atrium-pulmonary veins complex with half dose of intravenous gadolinium-based contrast agent. Technical feasibility and comparison with a conventional CEMRA, full contrast dose protocol.
Faggioni L; Zampa V; Ortori S; Picano E; De Lucia R; Soldati E; Bongiorni MG; Neri E; Bartolozzi C
Eur J Radiol; 2012 Feb; 81(2):250-6. PubMed ID: 21353421
[TBL] [Abstract][Full Text] [Related]
11. MRI findings of rapidly progressive hepatocellular carcinoma.
Kierans AS; Leonardou P; Hayashi P; Brubaker LM; Elazzazi M; Shaikh F; Semelka RC
Magn Reson Imaging; 2010 Jul; 28(6):790-6. PubMed ID: 20427139
[TBL] [Abstract][Full Text] [Related]
12. Hepatic arterial-phase dynamic gadolinium-enhanced MR imaging: optimization with a test examination and a power injector.
Earls JP; Rofsky NM; DeCorato DR; Krinsky GA; Weinreb JC
Radiology; 1997 Jan; 202(1):268-73. PubMed ID: 8988222
[TBL] [Abstract][Full Text] [Related]
13. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two different injection rates of gadoxetic acid for arterial phase MRI of the liver.
Chung SH; Kim MJ; Choi JY; Hong HS
J Magn Reson Imaging; 2010 Feb; 31(2):365-72. PubMed ID: 20099350
[TBL] [Abstract][Full Text] [Related]
15. Gadoxetic acid disodium-enhanced magnetic resonance imaging for biliary and vascular evaluations in preoperative living liver donors: comparison with gadobenate dimeglumine-enhanced MRI.
Lee MS; Lee JY; Kim SH; Park HS; Kim SH; Lee JM; Han JK; Choi BI
J Magn Reson Imaging; 2011 Jan; 33(1):149-59. PubMed ID: 21182133
[TBL] [Abstract][Full Text] [Related]
16. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy.
Spiewak M; Malek LA; Misko J; Chojnowska L; Milosz B; Klopotowski M; Petryka J; Dabrowski M; Kepka C; Ruzyllo W
Eur J Radiol; 2010 Jun; 74(3):e149-53. PubMed ID: 19523780
[TBL] [Abstract][Full Text] [Related]
17. Contrast-enhanced whole-heart coronary magnetic resonance angiography at 3.0 T: comparison with steady-state free precession technique at 1.5 T.
Liu X; Bi X; Huang J; Jerecic R; Carr J; Li D
Invest Radiol; 2008 Sep; 43(9):663-8. PubMed ID: 18708861
[TBL] [Abstract][Full Text] [Related]
18. Comparison of portal venous and delayed phases of gadolinium-enhanced magnetic resonance imaging study of cirrhotic liver for the detection of contrast washout of hypervascular hepatocellular carcinoma.
Cereser L; Furlan A; Bagatto D; Girometti R; Como G; Avellini C; Orsaria M; Zuiani C; Bazzocchi M
J Comput Assist Tomogr; 2010; 34(5):706-11. PubMed ID: 20861773
[TBL] [Abstract][Full Text] [Related]
19. Detection of hepatic hypovascular metastases: 3D gradient echo MRI using a hepatobiliary contrast agent.
Choi JY; Choi JS; Kim MJ; Lim JS; Park MS; Kim JH; Chung YE
J Magn Reson Imaging; 2010 Mar; 31(3):571-8. PubMed ID: 20187199
[TBL] [Abstract][Full Text] [Related]
20. Liver lesion characterization: the wrong choice of contrast agent can mislead the diagnosis of hemangioma.
Pradella S; Lucarini S; Colagrande S
AJR Am J Roentgenol; 2012 Nov; 199(5):W662. PubMed ID: 23096214
[No Abstract] [Full Text] [Related]
[Next] [New Search]
